Immunosensitization with a Bcl-2 small molecule inhibitor

Cancer Immunology, Immunotherapy

Volumn 58, Issue 5, 2009, Pages 699-708

  Begley, Jonathan ^a,b   Vo, Dan D ^a   Morris, Lilah F ^a   Bruhn, Kevin W ^a,c   Prins, Robert M ^d   Mok, Stephen ^a   Koya, Richard C ^a   Garban, Hermes J ^a   Comin Anduix, Begonya ^a   Craft, Noah ^c   Ribas, Antoni ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bcl 2; Melanoma; Rodent; Tumor immunotherapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MELANOMA ANTIGEN; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; RECOMBINANT GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CARCINOMA CELL; CHEMOSENSITIZATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LISTERIA MONOCYTOGENES; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; ANTIGENS, NEOPLASM; APOPTOSIS; BIPHENYL COMPOUNDS; CANCER VACCINES; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTRAMOLECULAR OXIDOREDUCTASES; KILLER CELLS, LYMPHOKINE-ACTIVATED; LISTERIA MONOCYTOGENES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM PROTEINS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, DEATH DOMAIN; RECOMBINANT FUSION PROTEINS; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61349161703     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0592-4     Document Type: Article

References (19)

1. GP Dunn AT Bruce H Ikeda LJ Old RD Schreiber 2002 Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 991 998
2. A Strasser 2005 The role of BH3-only proteins in the immune system Nat Rev Immunol 5 189 200
3. J Begley A Ribas 2008 Targeted therapies to improve tumor immunotherapy Clin Cancer Res 14 4385 4391 14/14/4385.[pii].10.1158/1078-0432.CCR-07-4804
4. T Oltersdorf SW Elmore AR Shoemaker RC Armstrong DJ Augeri BA Belli M Bruncko TL Deckwerth J Dinges PJ Hajduk MK Joseph S Kitada SJ Korsmeyer AR Kunzer A Letai C Li MJ Mitten DG Nettesheim S Ng PM Nimmer JM O'Connor A Oleksijew AM Petros JC Reed W Shen SK Tahir CB Thompson KJ Tomaselli B Wang MD Wendt H Zhang SW Fesik SH Rosenberg 2005 An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 677 681
5. J Kuroda H Puthalakath MS Cragg PN Kelly P Bouillet DC Huang S Kimura OG Ottmann BJ Druker A Villunger AW Roberts A Strasser 2006 Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic Proc Natl Acad Sci USA 103 14907 14912
6. S Alas CP Ng B Bonavida 2002 Rituximab modifies the cisplatin- mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma Clin Cancer Res 8 836 845
7. WW Overwijk MR Theoret SE Finkelstein DR Surman LA de Jong FA Vyth-Dreese TA Dellemijn PA Antony PJ Spiess DC Palmer DM Heimann CA Klebanoff Z Yu LN Hwang L Feigenbaum AM Kruisbeek SA Rosenberg NP Restifo 2003 Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 + T cells J Exp Med 198 569 580
8. A Ribas LH Butterfield WH McBride SM Jilani LA Bui CM Vollmer R Lau VB Dissette B Hu AY Chen JA Glaspy JS Economou 1997 Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells Cancer Res 57 2865 2869
9. KW Bruhn N Craft BD Nguyen J Yip JF Miller 2005 Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2 Vaccine 23 4263 4272
10. VP Badovinac KA Messingham A Jabbari JS Haring JT Harty 2005 Accelerated CD8 + T-cell memory and prime-boost response after dendritic-cell vaccination Nat Med 11 748 756
11. RM Prins KW Bruhn N Craft JW Lin CH Kim SK Odesa JF Miller LM Liau 2006 Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden Neurosurgery 58 169 178 discussion 169-178
12. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS (2005) Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother 1-9
13. AY Huang PH Gulden AS Woods MC Thomas CD Tong W Wang VH Engelhard G Pasternack R Cotter D Hunt DM Pardoll EM Jaffee 1996 The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product Proc Natl Acad Sci USA 93 9730 9735
14. JE Slansky FM Rattis LF Boyd T Fahmy EM Jaffee JP Schneck DH Margulies DM Pardoll 2000 Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex Immunity 13 529 538
15. LY Schumacher DD Vo HJ Garban B Comin-Anduix SK Owens VB Dissette JA Glaspy WH McBride B Bonavida JS Economou A Ribas 2006 Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade) J Immunol 176 4757 4765
16. A Ribas 2006 Update on immunotherapy for melanoma J Natl Compr Canc Netw 4 687 694
17. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915
18. Song JH, Kandasamy K, Kraft AS (2008) ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. doi: 10.1074/jbc.M802511200
19. S Huang FA Sinicrope 2008 BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells Cancer Res 68 2944 2951 10.1158/0008-5472.CAN-07-2508